Furthermore, inhibiting CCL4 with a specific antibody has been found to attenuate systemic inflammation, improve insulin resistance, and reduce circulating insulin levels in both type 2 diabetes animal models and metabolic syndrome animal models (51). This evidence concerns the gene INS and type 2 diabetes mellitus.